[1]
Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Current opinion in rheumatology. 2020 Jan:32(1):71-79. doi: 10.1097/BOR.0000000000000679. Epub
[PubMed PMID: 31688126]
Level 3 (low-level) evidence
[2]
Barkas F, Elisaf M, Liberopoulos E, Kalaitzidis R, Liamis G. Uric acid and incident chronic kidney disease in dyslipidemic individuals. Current medical research and opinion. 2018 Jul:34(7):1193-1199. doi: 10.1080/03007995.2017.1372157. Epub 2017 Sep 21
[PubMed PMID: 28836857]
Level 3 (low-level) evidence
[3]
Song D, Zhao X, Wang F, Wang G. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications. European journal of pharmacology. 2021 Sep 15:907():174291. doi: 10.1016/j.ejphar.2021.174291. Epub 2021 Jul 1
[PubMed PMID: 34216576]
[4]
Bhole V, Choi JW, Kim SW, de Vera M, Choi H. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. The American journal of medicine. 2010 Oct:123(10):957-61. doi: 10.1016/j.amjmed.2010.03.027. Epub
[PubMed PMID: 20920699]
[5]
Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. Journal of hypertension. 2015 Sep:33(9):1729-41; discussion 1741. doi: 10.1097/HJH.0000000000000701. Epub
[PubMed PMID: 26136207]
[6]
Borghi C. The role of uric acid in the development of cardiovascular disease. Current medical research and opinion. 2015:31 Suppl 2():1-2. doi: 10.1185/03007995.2015.1087985. Epub
[PubMed PMID: 26414729]
Level 3 (low-level) evidence
[7]
Sanchez-Lozada LG, Andres-Hernando A, Garcia-Arroyo FE, Cicerchi C, Li N, Kuwabara M, Roncal-Jimenez CA, Johnson RJ, Lanaspa MA. Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats. The Journal of biological chemistry. 2019 Mar 15:294(11):4272-4281. doi: 10.1074/jbc.RA118.006158. Epub 2019 Jan 16
[PubMed PMID: 30651350]
[8]
Russo E, Leoncini G, Esposito P, Garibotto G, Pontremoli R, Viazzi F. Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age. International journal of molecular sciences. 2020 Jun 24:21(12):. doi: 10.3390/ijms21124479. Epub 2020 Jun 24
[PubMed PMID: 32599713]
[9]
Dong H, Xu Y, Zhang X, Tian S. Visceral adiposity index is strongly associated with hyperuricemia independently of metabolic health and obesity phenotypes. Scientific reports. 2017 Aug 18:7(1):8822. doi: 10.1038/s41598-017-09455-z. Epub 2017 Aug 18
[PubMed PMID: 28821853]
[10]
Kahn AM. Effect of diuretics on the renal handling of urate. Seminars in nephrology. 1988 Sep:8(3):305-14
[PubMed PMID: 3059433]
[11]
Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ (Clinical research ed.). 1990 Apr 14:300(6730):975-8
[PubMed PMID: 2344503]
[12]
Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. Journal of the American Society of Nephrology : JASN. 2007 Feb:18(2):430-9
[PubMed PMID: 17229912]
[13]
Weinman EJ, Eknoyan G, Suki WN. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. The Journal of clinical investigation. 1975 Feb:55(2):283-91
[PubMed PMID: 1127100]
[14]
Steele TH, Oppenheimer S. Factors affecting urate excretion following diuretic administration in man. The American journal of medicine. 1969 Oct:47(4):564-74
[PubMed PMID: 4309843]
[15]
Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Archives of internal medicine. 2005 Apr 11:165(7):742-8
[PubMed PMID: 15824292]
[16]
Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. Journal of hypertension. 2001 Oct:19(10):1855-60
[PubMed PMID: 11593107]
Level 2 (mid-level) evidence
[17]
Weinberger MH. Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension. Hypertension (Dallas, Tex. : 1979). 1983 Sep-Oct:5(5 Pt 2):III132-8
[PubMed PMID: 6313523]
[18]
Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, Parks JH, Coe FL. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney international. 1999 Nov:56(5):1879-85
[PubMed PMID: 10571797]
[19]
Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension (Dallas, Tex. : 1979). 1995 Jul:26(1):112-7
[PubMed PMID: 7607713]
[20]
Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, Watanabe LA, Barragan J, Matadamas N, Mendiola A, Woo KS, Zhu JR, Mejia AD, Bunt T, Dumortier T, Smith RD. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clinical therapeutics. 2000 Oct:22(10):1186-203
[PubMed PMID: 11110230]
[21]
Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. Journal of hypertension. 1995 Nov:13(11):1343-51
[PubMed PMID: 8984133]
[22]
Buscemi S, Buscemi C, Borzì AM, Cosentino L, Rosafio G, Randazzo C, Colomba D, Di Raimondo D, Pluchinotta FR, Parrinello G. Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study). Metabolic syndrome and related disorders. 2020 Mar:18(2):110-118. doi: 10.1089/met.2019.0099. Epub 2020 Jan 23
[PubMed PMID: 31976814]
[23]
Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. American journal of translational research. 2020:12(7):3167-3181
[PubMed PMID: 32774692]
[24]
Williams LA. The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 2. International journal of pharmaceutical compounding. 2019 Jan-Feb:23(1):14-21
[PubMed PMID: 30668531]
[25]
Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. The American journal of medicine. 1987 Mar:82(3):421-6
[PubMed PMID: 3826098]
[26]
Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology (Oxford, England). 2019 Dec 1:58(12):2177-2180. doi: 10.1093/rheumatology/kez196. Epub
[PubMed PMID: 31168609]
[27]
Gosling AL, Matisoo-Smith E, Merriman TR. Hyperuricaemia in the Pacific: why the elevated serum urate levels? Rheumatology international. 2014 Jun:34(6):743-57. doi: 10.1007/s00296-013-2922-x. Epub 2013 Dec 31
[PubMed PMID: 24378761]
[28]
Wu X, You C. The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics. PeerJ. 2023:11():e14554. doi: 10.7717/peerj.14554. Epub 2023 Jan 6
[PubMed PMID: 36632144]
[29]
Yokokawa H, Fukuda H, Suzuki A, Fujibayashi K, Naito T, Uehara Y, Nakayama A, Matsuo H, Sanada H, Jose PA, Miwa Y, Hisaoka T, Isonuma H. Association Between Serum Uric Acid Levels/Hyperuricemia and Hypertension Among 85,286 Japanese Workers. Journal of clinical hypertension (Greenwich, Conn.). 2016 Jan:18(1):53-9. doi: 10.1111/jch.12627. Epub 2015 Jul 25
[PubMed PMID: 26212524]
[30]
Paquot N, Scheen AJ. [DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes]. Revue medicale suisse. 2017 Aug 23:13(571):1410-1415
[PubMed PMID: 28837277]
[31]
Tian S, Liu Y, Xu Y, Feng A. Does obesity modify the epidemiological association between hyperuricemia and the prevalence of hypertension among Northern Chinese community-dwelling people? A Chinese population-based study. BMJ open. 2019 Nov 21:9(11):e031803. doi: 10.1136/bmjopen-2019-031803. Epub 2019 Nov 21
[PubMed PMID: 31753884]
Level 2 (mid-level) evidence
[32]
Borghi C, Agabiti-Rosei E, Johnson RJ, Kielstein JT, Lurbe E, Mancia G, Redon J, Stack AG, Tsioufis KP. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. European journal of internal medicine. 2020 Oct:80():1-11. doi: 10.1016/j.ejim.2020.07.006. Epub 2020 Jul 29
[PubMed PMID: 32739239]
[33]
Ejaz AA, Johnson RJ, Shimada M, Mohandas R, Alquadan KF, Beaver TM, Lapsia V, Dass B. The Role of Uric Acid in Acute Kidney Injury. Nephron. 2019:142(4):275-283. doi: 10.1159/000499939. Epub 2019 Apr 16
[PubMed PMID: 30991383]
[34]
Hassan W, Shrestha P, Sumida K, Thomas F, Sweeney PL, Potukuchi PK, Rhee CM, Streja E, Kalantar-Zadeh K, Kovesdy CP. Association of Uric Acid-Lowering Therapy With Incident Chronic Kidney Disease. JAMA network open. 2022 Jun 1:5(6):e2215878. doi: 10.1001/jamanetworkopen.2022.15878. Epub 2022 Jun 1
[PubMed PMID: 35657621]
[35]
Rincon-Choles H, Jolly SE, Arrigain S, Konig V, Schold JD, Nakhoul G, Navaneethan SD, Nally JV Jr, Rothberg MB. Impact of Uric Acid Levels on Kidney Disease Progression. American journal of nephrology. 2017:46(4):315-322. doi: 10.1159/000481460. Epub 2017 Oct 13
[PubMed PMID: 29032376]
[36]
Yakupova SP. Gout. New opportunities of diagnosis and treatment. Terapevticheskii arkhiv. 2018 May 11:90(5):88-92. doi: 10.26442/terarkh201890588-92. Epub
[PubMed PMID: 30701896]
[37]
Shiraishi H, Une H. The effect of the interaction between obesity and drinking on hyperuricemia in Japanese male office workers. Journal of epidemiology. 2009:19(1):12-6
[PubMed PMID: 19164873]
[38]
Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, de Brouwer APM, Christodoulou J. Phosphoribosylpyrophosphate Synthetase Superactivity. GeneReviews(®). 1993:():
[PubMed PMID: 20301734]
[39]
Dewulf JP, Marie S, Nassogne MC. Disorders of purine biosynthesis metabolism. Molecular genetics and metabolism. 2022 Jul:136(3):190-198. doi: 10.1016/j.ymgme.2021.12.016. Epub 2021 Dec 30
[PubMed PMID: 34998670]
[40]
Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet (London, England). 2021 May 15:397(10287):1843-1855. doi: 10.1016/S0140-6736(21)00569-9. Epub 2021 Mar 30
[PubMed PMID: 33798500]
[41]
Zhao Z, Liu J, Yuan L, Yang Z, Kuang P, Liao H, Luo J, Feng H, Zheng F, Chen Y, Wu T, Guo J, Cao Y, Yang Y, Lin C, Zhang Q, Chen J, Pang J. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents. European journal of medicinal chemistry. 2022 Nov 15:242():114682. doi: 10.1016/j.ejmech.2022.114682. Epub 2022 Aug 18
[PubMed PMID: 36001935]
[42]
Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Advances in chronic kidney disease. 2012 Nov:19(6):358-71. doi: 10.1053/j.ackd.2012.07.009. Epub
[PubMed PMID: 23089270]
Level 3 (low-level) evidence
[45]
Yang N, Yu Y, Zhang A, Estill J, Wang X, Zheng M, Zhou Q, Zhang J, Luo X, Qian C, Mao Y, Wang Q, Yang Y, Chen Y. Reporting, presentation and wording of recommendations in clinical practice guideline for gout: a systematic analysis. BMJ open. 2019 Jan 29:9(1):e024315. doi: 10.1136/bmjopen-2018-024315. Epub 2019 Jan 29
[PubMed PMID: 30700479]
Level 2 (mid-level) evidence
[46]
Alqarni NA, Hassan AH. Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia. Saudi medical journal. 2018 Dec:39(12):1218-1225. doi: 10.15537/smj.2018.12.23715. Epub
[PubMed PMID: 30520504]
[47]
Engel B, Schacher S, Weckbecker K, Stausberg A, Gräff I. [Acute Gout in Emergency Admissions - Patient Characteristics and Adherence of Care Processes to Current Guidelines]. Zeitschrift fur Orthopadie und Unfallchirurgie. 2018 Dec:156(6):653-661. doi: 10.1055/a-0619-6216. Epub 2018 Jul 9
[PubMed PMID: 29986356]
[48]
Buzas R, Tautu OF, Dorobantu M, Ivan V, Lighezan D. Serum uric acid and arterial hypertension-Data from Sephar III survey. PloS one. 2018:13(7):e0199865. doi: 10.1371/journal.pone.0199865. Epub 2018 Jul 2
[PubMed PMID: 29966019]
Level 3 (low-level) evidence
[49]
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & rheumatology (Hoboken, N.J.). 2020 Jun:72(6):879-895. doi: 10.1002/art.41247. Epub 2020 May 11
[PubMed PMID: 32390306]
[52]
Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and therapeutic uses. Seminars in arthritis and rheumatism. 2015 Dec:45(3):341-50. doi: 10.1016/j.semarthrit.2015.06.013. Epub 2015 Jun 26
[PubMed PMID: 26228647]
[53]
Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, Doherty S, Duley L, Hatton R, Rees F, Stevenson M, Zhang W. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet (London, England). 2018 Oct 20:392(10156):1403-1412. doi: 10.1016/S0140-6736(18)32158-5. Epub
[PubMed PMID: 30343856]
Level 1 (high-level) evidence
[54]
Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002 May 23:417(6887):447-52
[PubMed PMID: 12024214]
[55]
Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, Elisaf MS. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. American heart journal. 2004 Oct:148(4):635-40
[PubMed PMID: 15459594]
[56]
Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford, England). 2003 Feb:42(2):321-5
[PubMed PMID: 12595630]
[57]
Granados JC, Bhatnagar V, Nigam SK. Blockade of Organic Anion Transport in Humans After Treatment With the Drug Probenecid Leads to Major Metabolic Alterations in Plasma and Urine. Clinical pharmacology and therapeutics. 2022 Sep:112(3):653-664. doi: 10.1002/cpt.2630. Epub 2022 May 22
[PubMed PMID: 35490380]
[59]
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Lioté F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis care & research. 2012 Oct:64(10):1431-46. doi: 10.1002/acr.21772. Epub
[PubMed PMID: 23024028]
Level 1 (high-level) evidence
[61]
Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug safety. 2008:31(8):643-65
[PubMed PMID: 18636784]
[62]
Reinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar MA, Brouwers JR. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Annals of the rheumatic diseases. 2009 Jan:68(1):51-6. doi: 10.1136/ard.2007.083071. Epub 2008 Feb 4
[PubMed PMID: 18250112]
Level 1 (high-level) evidence
[63]
Hosoya T, Furuno K, Kanda S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clinical and experimental nephrology. 2020 Mar:24(Suppl 1):71-79. doi: 10.1007/s10157-020-01851-6. Epub 2020 Jan 22
[PubMed PMID: 31970593]
[64]
Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clinical and experimental nephrology. 2020 Mar:24(Suppl 1):62-70. doi: 10.1007/s10157-020-01849-0. Epub 2020 Jan 24
[PubMed PMID: 31980978]
Level 1 (high-level) evidence
[65]
Iqbal A, Iqbal K, Farid E, Ishaque A, Hasanain M, Bin Arif T, Arshad Ali S, Rathore SS, Malik M. Efficacy and Safety of Dotinurad in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2021 Apr 12:13(4):e14428. doi: 10.7759/cureus.14428. Epub 2021 Apr 12
[PubMed PMID: 33996294]
Level 1 (high-level) evidence
[66]
Omura K, Miyata K, Kobashi S, Ito A, Fushimi M, Uda J, Sasaki T, Iwanaga T, Ohashi T. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor. Drug metabolism and pharmacokinetics. 2020 Jun:35(3):313-320. doi: 10.1016/j.dmpk.2020.03.002. Epub 2020 Mar 9
[PubMed PMID: 32327267]
[67]
Kuriyama S. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia. Clinical and experimental nephrology. 2020 Mar:24(Suppl 1):1-5. doi: 10.1007/s10157-019-01811-9. Epub 2019 Nov 21
[PubMed PMID: 31754883]
[68]
Wu JY, Chang YT, Lin YC, Lee CH, Loh EW, Wu MY, Chang YS, Tam KW. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmacotherapy. 2018 Nov:38(11):1106-1119. doi: 10.1002/phar.2183. Epub 2018 Oct 17
[PubMed PMID: 30246299]
Level 1 (high-level) evidence
[69]
Cicero AFG, Fogacci F, Kuwabara M, Borghi C. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina (Kaunas, Lithuania). 2021 Jan 10:57(1):. doi: 10.3390/medicina57010058. Epub 2021 Jan 10
[PubMed PMID: 33435164]
[70]
Fam AG. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Current rheumatology reports. 2001 Feb:3(1):29-35
[PubMed PMID: 11177768]
[74]
Park S, Lee JP, Kim DK, Kim YS, Lim CS. Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression. PloS one. 2022:17(2):e0264627. doi: 10.1371/journal.pone.0264627. Epub 2022 Feb 28
[PubMed PMID: 35226683]
[75]
Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2006 Apr:12(2):61-5
[PubMed PMID: 16601538]
[76]
Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis and rheumatism. 1986 Jan:29(1):82-7
[PubMed PMID: 3947418]
[77]
Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. The American journal of medicine. 1984 Jan:76(1):47-56
[PubMed PMID: 6691361]
[78]
Yaseen W, Auguste B, Zipursky J. Allopurinol hypersensitivity syndrome. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2023 Apr 3:195(13):E483. doi: 10.1503/cmaj.221575. Epub
[PubMed PMID: 37011932]
[79]
Quach C, Galen BT. HLA-B*5801 Testing to Prevent Allopurinol Hypersensitivity Syndrome: A Teachable Moment. JAMA internal medicine. 2018 Sep 1:178(9):1260-1261. doi: 10.1001/jamainternmed.2018.3556. Epub
[PubMed PMID: 30083702]
[80]
Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis and rheumatism. 2012 Aug:64(8):2529-36. doi: 10.1002/art.34488. Epub
[PubMed PMID: 22488501]
[81]
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. The New England journal of medicine. 2005 Dec 8:353(23):2450-61
[PubMed PMID: 16339094]
[82]
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, CARES Investigators. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. The New England journal of medicine. 2018 Mar 29:378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12
[PubMed PMID: 29527974]
[84]
Ishikawa T, Maeda T, Hashimoto T, Nakagawa T, Ichikawa K, Sato Y, Kanno Y. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study. Clinical drug investigation. 2020 Sep:40(9):847-859. doi: 10.1007/s40261-020-00941-3. Epub
[PubMed PMID: 32621143]
Level 2 (mid-level) evidence
[85]
Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Seminars in arthritis and rheumatism. 2020 Jun:50(3S):S31-S38. doi: 10.1016/j.semarthrit.2020.04.011. Epub
[PubMed PMID: 32620200]
Level 3 (low-level) evidence
[86]
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the rheumatic diseases. 2017 Jan:76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25
[PubMed PMID: 27457514]
[87]
Schlesinger N, Yasothan U, Kirkpatrick P. Pegloticase. Nature reviews. Drug discovery. 2011 Jan:10(1):17-8. doi: 10.1038/nrd3349. Epub
[PubMed PMID: 21193861]
Level 3 (low-level) evidence
[88]
Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. International journal of medical sciences. 2007 Mar 2:4(2):83-93
[PubMed PMID: 17396159]
Level 3 (low-level) evidence
[89]
Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proceedings (Baylor University. Medical Center). 2005 Jul:18(3):275-9
[PubMed PMID: 16200184]
Level 3 (low-level) evidence
[90]
Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. The American journal of medicine. 2004 Apr 15:116(8):546-54
[PubMed PMID: 15063817]
[91]
Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Feb 1:19(3):697-704
[PubMed PMID: 11157020]
[92]
Majumdar S, Sharma N, Sengar M, Thorat J, Nayak L, Bonda A, Bagal B, Rajendra A, Sethi A, Jain H. A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome. Leukemia & lymphoma. 2023 Mar:64(3):628-638. doi: 10.1080/10428194.2023.2167491. Epub 2023 Mar 8
[PubMed PMID: 36891578]
Level 3 (low-level) evidence
[93]
Shaikh SA, Marini BL, Hough SM, Perissinotti AJ. Rational use of rasburicase for the treatment and management of tumor lysis syndrome. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2018 Apr:24(3):176-184. doi: 10.1177/1078155216687152. Epub 2017 Jan 11
[PubMed PMID: 28077046]
Level 3 (low-level) evidence
[96]
Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Advanced drug delivery reviews. 2008 Jan 3:60(1):59-68
[PubMed PMID: 17826865]
Level 3 (low-level) evidence
[97]
Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfield MS. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis and rheumatism. 2007 Mar:56(3):1021-8
[PubMed PMID: 17328081]
[98]
Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis research & therapy. 2014 Mar 7:16(2):R63. doi: 10.1186/ar4500. Epub 2014 Mar 7
[PubMed PMID: 24602182]
Level 3 (low-level) evidence
[99]
Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW 2nd, Hamburger SA, Becker MA. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17:306(7):711-20. doi: 10.1001/jama.2011.1169. Epub
[PubMed PMID: 21846852]
Level 1 (high-level) evidence
[100]
Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z, Pegloticase Phase 2 Study Investigators. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis and rheumatism. 2008 Sep:58(9):2882-91. doi: 10.1002/art.23810. Epub
[PubMed PMID: 18759308]
Level 1 (high-level) evidence
[101]
Botson JK, Saag K, Peterson J, Parikh N, Ong S, La D, LoCicero K, Obermeyer K, Xin Y, Chamberlain J, LaMoreaux B, Verma S, Sainati S, Grewal S, Majjhoo A, Tesser JRP, Weinblatt ME. A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis & rheumatology (Hoboken, N.J.). 2023 Feb:75(2):293-304. doi: 10.1002/art.42335. Epub 2022 Dec 16
[PubMed PMID: 36099211]
Level 1 (high-level) evidence
[102]
Botson JK, Obermeyer K, LaMoreaux B, Zhao L, Weinblatt ME, Peterson J. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial. Arthritis research & therapy. 2022 Dec 27:24(1):281. doi: 10.1186/s13075-022-02979-4. Epub 2022 Dec 27
[PubMed PMID: 36575505]
Level 3 (low-level) evidence
[104]
Leslie SW, Sajjad H, Bashir K. 24-Hour Urine Testing for Nephrolithiasis: Interpretation and Treatment Guidelines. StatPearls. 2024 Jan:():
[PubMed PMID: 29494055]
[107]
Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT, Hsieh SC, Hsieh TY, Hsu PF, Kuo CF, Kuo MC, Lam HC, Lee IT, Liang TH, Lin HY, Lin SC, Tsai WP, Tsay GJ, Wei JC, Yang CH, Tsai WC. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. International journal of rheumatic diseases. 2018 Apr:21(4):772-787. doi: 10.1111/1756-185X.13266. Epub 2018 Jan 24
[PubMed PMID: 29363262]
Level 3 (low-level) evidence
[108]
Janssen CA, Jansen TLTA, Oude Voshaar MAH, Vonkeman HE, van de Laar MAFJ. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients. Rheumatology international. 2017 Sep:37(9):1435-1440. doi: 10.1007/s00296-017-3777-3. Epub 2017 Jul 26
[PubMed PMID: 28748426]
Level 2 (mid-level) evidence